As traditional strategies to manage obesity, such as diet, exercise, or surgery, often yield limited long-term success (Hall and Kahan, 2018; Wadden et al., 2020), and pharmacological interventions, including GLP1 agonists and other synthetic drugs, can cause undesirable side effects (Coulter et al., 2018), there is a growing need for innovative pharmacological approaches. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.